Case Study: Sanofi assesses novel biotherapeutic developability with Genedata

Sanofi accelerates biotherapeutic developability analysis with Genedata to cut later-stage attrition and speed time to clinic

Sanofi required a systematic approach to assess the developability of its novel biotherapeutics, which often have unpredictable behaviors. To meet this challenge, they utilized the Genedata biopharma platform, specifically Genedata Expressionist, for comprehensive molecular characterization.

Genedata provided a unified, data-driven framework integrating AI-driven developability prediction, antibody informatics, and in silico screening software. This solution enabled Sanofi's scientists to rapidly assess molecular stability, manufacturability, and quality early in discovery. The results included significantly lower attrition rates in later development stages, less problematic processes, and a faster time to clinic with best-in-class biotherapeutics.

Sanofi